Linogliride

This classification denotes an anti-diabetic agent with the molecular formula C16H22N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 7E521JYJ4X, chemically known as 4-morpholinecarboximidamide, n-(1-methyl-2-pyrrolidinylidene)-n-phenyl- but more generally known as linogliride, which bears US NIH Compound Identifier 6536869. European Medicines Agency schedules Linogliride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08521MIG. The term LINOGLIRIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 37, No. 6, 1983, List 23). LINOGLIRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule linogliride under HS 29349990 and SITC 51579. As of Q4 2014, LINOGLIRIDE remains US FDA's Preferred Term for this commodity. Linogliride bears US NLM identifiers UMLS ID C0065013 and NCI Concept Code C66015. SMILES: O1CCN(CC1)/C(=N\C1CCCCC1)/N=C1/N(CCC1)C.